Radionuclide-Drug Conjugates (RDCs)
Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.
Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (226)
Related Products (226)
-
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
-
DOTA-Bombesin (1-14) TFA
0 ImagesCat. No.: HY-P10729APurity: 98.10%DOTA-Bombesin (1-14) TFA is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) TFA is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14)TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
Maleimide-DTPA
0 ImagesCat. No.: HY-W738256CAS No.: 180152-82-3Synonyms: MDTPAMaleimide-DTPA (MDTPA) is a maleimide-functionalized bifunctional chelator that enables site-specific conjugation via a thioether bond to single-domain antibody fragments (sdAb) containing free cysteine, and mediates 111In radiolabeling. DTPA-2Rs15d-HLC, formed by the conjugation of Maleimide-DTPA with anti-HER2 sdAb 2Rs15d-HLC, retains high affinity for HER2 with a Kd of 5.9 nM, and maintains targeting ability to HER2-positive cells and tumors after 111In labeling. Maleimide-DTPA can be used for radiotracer construction, SPECT molecular imaging, and HER2-positive tumor research.
-
DOTA-EB-TATE
0 ImagesCat. No.: HY-P10741CAS No.: 2151063-66-8DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
HQ-415
0 ImagesHQ-415 is a biologically active metal chelator related to Clioquinol (HY-14603), with an EC50 of 15 μM.
-
Polyamidoamine (20% in methanol)
0 ImagesCat. No.: HY-164657CAS No.: 153891-46-4Synonyms: PAMAMPolyamidoamine (PAMAM) (20% in methanol) is a new type of drug carrier that has drug encapsulation capabilities internally and biocompatibility on the surface, and can be used as a drug delivery system.
-
Cys-FAP targeting peptide for FXX489 TFA
0 ImagesCat. No.: HY-P10945BCys-FAP targeting peptide for FXX489 TFA is a version of the FAP-targeting peptide for FXX489 TFA that incorporates a Cys (cysteine) group. It can undergo conjugation reactions via the thiol group of the cysteine residue.
-
PSMA-D5
0 ImagesPSMA-D5 has a binding affinity for PSMA with a Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors. PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
Tz-Ph-PEG4-NH-DOTA tetraTFA
0 ImagesCat. No.: HY-180447APurity: 98.01%Tz-Ph-PEG4-NH-DOTA (Compound 10) tetraTFA is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA tetraTFA can be used in PET imaging and tumor research.
-
DOTA-PSMA-EB-01
0 ImagesCat. No.: HY-158266Synonyms: LNC1003DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors. DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
Tz-Ph-PEG4-NH-DOTA
0 ImagesCat. No.: HY-180447CAS No.: 2756465-66-2Tz-Ph-PEG4-NH-DOTA (Compound 10) is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA can be used in PET imaging and tumor research.
-
MIP-1095 TFA
0 ImagesCat. No.: HY-123733APurity: 99.76%Synonyms: RPS-001 TFAMIP-1095 TFA (RPS-001 TFA) is a PSMA inhibitor with a Ki value of 0.24 nM. MIP-1095 TFA binds to PSMA with high affinity and can be internalized into PSMA-expressing cancer cells. When radiolabeled with 123I, 124I or 131I, MIP-1095 TFA enables SPECT/CT imaging, PET/CT imaging or targeted radiation delivery, respectively. 131I-MIP-1095 TFA can alter serum PSA levels and relieve bone pain. MIP-1095 TFA can be used in research related to metastatic castration-resistant prostate cancer.
-
BCN-DOTA
0 ImagesCat. No.: HY-164574CAS No.: 2565792-45-0BCN-DOTA is a cyclooctyne-linked DOTA chelator. BCN-DOTA integrates BCN and DOTA, enabling conjugation with azide-functionalized groups via the click chemistry properties of BCN, while binding to metal ions through the coordination capacity of DOTA. BCN-DOTA can serve as a radionuclide-drug conjugate (RDC) to target specific biomolecules, cells or tissues after radiolabeling with zirconium-89. BCN-DOTA is applicable to research related to PET imaging and targeted therapy.
-
NOTA-Pep-1L
0 ImagesCat. No.: HY-P10292Purity: 98.60%NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging. NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
PDI2
0 ImagesSynonyms: PSMA-DOTA-PEI2PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.
-
NOTA-FZCD-3
0 ImagesCat. No.: HY-P11844Purity: 98.43%NOTA-FZCD-3 is a NOTA (HY-134418)-labeled FZCD-3 polypeptide precursor that targets cathepsin D (CTSD) with a KD of 0.65 μM. NOTA-FZCD-3 binds specifically to the active site of CTSD, exhibits rapid in vivo clearance properties, and remains stable in blood for more than 2 h. NOTA-FZCD-3 can be used in studies monitoring CTSD-positive tumors.
-
Pentetreotide
0 ImagesPentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with 111In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis.
